GlassScriptPhysician profile
Sachiko Nakashima
NPI 1699029561
$1,634.41
in general payments reported to CMS, 2019-2025
19 companies · $452 in 2025
The $452 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $170 · 2022: $373 · 2023: $332 · 2024: $307 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.39 | 2021-2025 | |
| Astellas Pharma US INC | $262.37 | 2022-2025 | Veozah |
| Lilly USA, LLC | $247.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $99.65 | 2021-2024 | |
| Exact Sciences Corporation | $79.21 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $56.36 | 2023-2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $54.26 | 2022 | |
| Dexcom, INC. | $53.96 | 2022-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $48.79 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $45.48 | 2021-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $36.86 | 2024-2025 | Airsupra |
| Abbott Laboratories | $31.90 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.55 | 2025 | Caplyta |
| Shield Therapeutics INC | $22.23 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.71 | 2025 | Jardiance |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.58 | 2023 | Rexulti |
| Vistapharm, INC. | $14.07 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $13.78 | 2022 | |
| Eisai INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachiko Nakashima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.